Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease

Loes H. C. Nissen; Eemke L. Assendorp; Rachel S. van der Post; Lauranne A. A. P. Derikx; Dirk J. de Jong; Wietske Kievit; Marieke Pierik; Tim van den Heuvel; Rob Verhoeven; Lucy I. H. Overbeek; Frank Hoentjen; Iris D. Nagtegaal

doi:10.15403/jgld.2014.1121.254.nis

Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease

Loes H. C. Nissen^*, Eemke L. Assendorp, Rachel S. van der Post, Lauranne A. A. P. Derikx, Dirk J. de Jong, Wietske Kievit, Marieke Pierik, Tim van den Heuvel, Rob Verhoeven, Lucy I. H. Overbeek, Frank Hoentjen, Iris D. Nagtegaal

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background & Aims: Both chronic inflammation and reduced immunosurveillance contribute to malignancy development in inflammatory bowel disease (IBD). Previous literature suggests that especially Crohn's disease patients are at an increased risk for developing gastric cancer (GC). This study aimed to identify risk factors for GC development in IBD and to compare the clinical characteristics of GC in IBD to those in the general population. Methods: We retrospectively searched the Dutch Pathology Database to identify all Dutch IBD patients with GC between January 2004 and December 2008. Two case-control studies were performed. I: to identify risk factors for GC in IBD, with controls from the IBD South Limburg (IBDSL) population-based cohort; and II: to compare GC disease course in IBD patients with the general population. General population data were obtained from the Eindhoven Cancer Registry (ECR). Results: We included 59 patients with IBD and GC (cases). Cases were significantly older at IBD diagnosis than IBDSL controls (median age 61 years versus 40; p

Original language	English
Pages (from-to)	431-440
Journal	Journal of Gastrointestinal and Liver Diseases
Volume	25
Issue number	4
DOIs	https://doi.org/10.15403/jgld.2014.1121.254.nis
Publication status	Published - Dec 2016

Keywords

inflammatory bowel diseases
gastric cancer
immunosuppressive therapy

Access to Document

10.15403/jgld.2014.1121.254.nis

Cite this

Nissen, L. H. C., Assendorp, E. L., van der Post, R. S., Derikx, L. A. A. P., de Jong, D. J., Kievit, W., Pierik, M., van den Heuvel, T., Verhoeven, R., Overbeek, L. I. H., Hoentjen, F., & Nagtegaal, I. D. (2016). Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease. Journal of Gastrointestinal and Liver Diseases, 25(4), 431-440. https://doi.org/10.15403/jgld.2014.1121.254.nis

@article{8471161f31834b57b27c3a47650592c7,

title = "Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease",

abstract = "Background & Aims: Both chronic inflammation and reduced immunosurveillance contribute to malignancy development in inflammatory bowel disease (IBD). Previous literature suggests that especially Crohn's disease patients are at an increased risk for developing gastric cancer (GC). This study aimed to identify risk factors for GC development in IBD and to compare the clinical characteristics of GC in IBD to those in the general population. Methods: We retrospectively searched the Dutch Pathology Database to identify all Dutch IBD patients with GC between January 2004 and December 2008. Two case-control studies were performed. I: to identify risk factors for GC in IBD, with controls from the IBD South Limburg (IBDSL) population-based cohort; and II: to compare GC disease course in IBD patients with the general population. General population data were obtained from the Eindhoven Cancer Registry (ECR). Results: We included 59 patients with IBD and GC (cases). Cases were significantly older at IBD diagnosis than IBDSL controls (median age 61 years versus 40; p",

keywords = "inflammatory bowel diseases, gastric cancer, immunosuppressive therapy",

author = "Nissen, {Loes H. C.} and Assendorp, {Eemke L.} and {van der Post}, {Rachel S.} and Derikx, {Lauranne A. A. P.} and {de Jong}, {Dirk J.} and Wietske Kievit and Marieke Pierik and {van den Heuvel}, Tim and Rob Verhoeven and Overbeek, {Lucy I. H.} and Frank Hoentjen and Nagtegaal, {Iris D.}",

year = "2016",

month = dec,

doi = "10.15403/jgld.2014.1121.254.nis",

language = "English",

volume = "25",

pages = "431--440",

journal = "Journal of Gastrointestinal and Liver Diseases",

issn = "1841-8724",

publisher = "Romanian Society of Gastroenterology",

number = "4",

}

Nissen, LHC, Assendorp, EL, van der Post, RS, Derikx, LAAP, de Jong, DJ, Kievit, W, Pierik, M, van den Heuvel, T, Verhoeven, R, Overbeek, LIH, Hoentjen, F & Nagtegaal, ID 2016, 'Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease', Journal of Gastrointestinal and Liver Diseases, vol. 25, no. 4, pp. 431-440. https://doi.org/10.15403/jgld.2014.1121.254.nis

TY - JOUR

T1 - Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease

AU - Nissen, Loes H. C.

AU - Assendorp, Eemke L.

AU - van der Post, Rachel S.

AU - Derikx, Lauranne A. A. P.

AU - de Jong, Dirk J.

AU - Kievit, Wietske

AU - Pierik, Marieke

AU - van den Heuvel, Tim

AU - Verhoeven, Rob

AU - Overbeek, Lucy I. H.

AU - Hoentjen, Frank

AU - Nagtegaal, Iris D.

PY - 2016/12

Y1 - 2016/12

N2 - Background & Aims: Both chronic inflammation and reduced immunosurveillance contribute to malignancy development in inflammatory bowel disease (IBD). Previous literature suggests that especially Crohn's disease patients are at an increased risk for developing gastric cancer (GC). This study aimed to identify risk factors for GC development in IBD and to compare the clinical characteristics of GC in IBD to those in the general population. Methods: We retrospectively searched the Dutch Pathology Database to identify all Dutch IBD patients with GC between January 2004 and December 2008. Two case-control studies were performed. I: to identify risk factors for GC in IBD, with controls from the IBD South Limburg (IBDSL) population-based cohort; and II: to compare GC disease course in IBD patients with the general population. General population data were obtained from the Eindhoven Cancer Registry (ECR). Results: We included 59 patients with IBD and GC (cases). Cases were significantly older at IBD diagnosis than IBDSL controls (median age 61 years versus 40; p

AB - Background & Aims: Both chronic inflammation and reduced immunosurveillance contribute to malignancy development in inflammatory bowel disease (IBD). Previous literature suggests that especially Crohn's disease patients are at an increased risk for developing gastric cancer (GC). This study aimed to identify risk factors for GC development in IBD and to compare the clinical characteristics of GC in IBD to those in the general population. Methods: We retrospectively searched the Dutch Pathology Database to identify all Dutch IBD patients with GC between January 2004 and December 2008. Two case-control studies were performed. I: to identify risk factors for GC in IBD, with controls from the IBD South Limburg (IBDSL) population-based cohort; and II: to compare GC disease course in IBD patients with the general population. General population data were obtained from the Eindhoven Cancer Registry (ECR). Results: We included 59 patients with IBD and GC (cases). Cases were significantly older at IBD diagnosis than IBDSL controls (median age 61 years versus 40; p

KW - inflammatory bowel diseases

KW - gastric cancer

KW - immunosuppressive therapy

U2 - 10.15403/jgld.2014.1121.254.nis

DO - 10.15403/jgld.2014.1121.254.nis

M3 - Article

C2 - 27981298

SN - 1841-8724

VL - 25

SP - 431

EP - 440

JO - Journal of Gastrointestinal and Liver Diseases

JF - Journal of Gastrointestinal and Liver Diseases

IS - 4

ER -